Most Read

The company’s investigational new drug application (IND) for the clinical trial will be on partial clinical hold until the regulator receives satisfying answers for the questions. The partial

Nucala has been approved to treat adult and paediatric patients aged 12 years and older with HES ≥ six months without an identifiable non-haematologic secondary cause. Mepolizumab, the

The scope of the deal comprises technical transfer, and fill and finish manufacture of J&J’s SARS-CoV-2 vaccine candidate. GRAM stated that it is having modern equipment to manufacture

The trial’s top-line data from 203 participants demonstrate that severe or critical Covid-19 patients treated with SACCOVID witnessed speedy recovery and a significant reduction in disease progression to

The late-stage trial called ENSEMBLE to be held in multiple countries across three countries will study the safety and efficacy of a single dosage of JNJ-78436735 in comparison

The companies are seeking approval for the use of ide-cel in adult patients with the disease who have been subjected to least three prior therapies. The investigational cell

The phase III clinical trials will assess the efficacy and safety of the CoronaVac vaccine candidate, which is developed by Sinovac Life Sciences. Sinovac’s case-driven, randomised, double-blinded and

The CheckMate -649 trial demonstrated statistically significant and clinically meaningful improvement in both the parameters for the Opdivo + chemotherapy arm compared to chemotherapy alone. The late-stage trial

The deal also allows Inflazome to secure additional contingent payments based on the achievement of certain predetermined milestones. Based in Dublin, Inflazome is engaged in the development of